Advertisement

Pharmacy

Advertisement

After several years of declining revenues, top generic drug maker Teva Pharmaceuticals will turn to high-priced biotech medications in an effort to jumpstart growth, The Wall Street Journal reports.

A federal judge has ruled that AbbVie must turn over documents in a lawsuit that accuses the drugmaker of using "unclean hands" to create a thicket of patents to protect its best-selling drug Humira from competition, according to STAT.

Advertisement